Trial Profile
The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
- Indications Diabetes mellitus; Essential hypertension; Renal failure
- Focus Therapeutic Use
- Acronyms HARIMAYA study
- 19 May 2016 New trial record